| 945974-78-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• CAS: 945974-78-7
• 化学式: C₁₈H₂₁IN₄O₂
• 分子量: 452.295
• InChiKey: ITZVSWXQLYEOAC-AULYBMBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  25.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  90.04
• 氢给体数：
  4.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  、 4'-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)联苯-4-醇 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 8.33h， 生成 N-[3-(4'-hydroxy-1,1'-biphenyl-4-yl)-1,4-dihydroindeno[1,2-c]pyrazol-6-yl]-2-[trans-(4-hydroxycyclohexyl)amino]acetamide
  参考文献：
  名称：

  1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Extended exploration on phenyl ring substitutions and preliminary ADME/PK studies

  摘要：

  A study on substitutions at the four open positions on the phenyl ring of the 1,4-dihydroindeno[1,2-c]pyrazoles as potent CHK-1 inhibitors is described. Bis-substitution at both the 6- and 7-positions led to inhibitors with IC50 values below 0.3 nM. The compound with the best overall activities (36) was able to potentiate the anti-proliferative effect of doxorubicin in HeLa cells by at least 47-fold. Physicochemical, metabolic, and pharmacokinetic properties of selected inhibitors are also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.055
• 作为产物：
  描述：

  6-bromo-1,4-dihydroindeno[1,2-c]pyrazole 在 N-碘代丁二酰亚胺 、 2-(三甲基硅烷基)乙氧甲基氯 、 sodium hydride 、 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成
  参考文献：
  名称：

  1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Extended exploration on phenyl ring substitutions and preliminary ADME/PK studies

  摘要：

  A study on substitutions at the four open positions on the phenyl ring of the 1,4-dihydroindeno[1,2-c]pyrazoles as potent CHK-1 inhibitors is described. Bis-substitution at both the 6- and 7-positions led to inhibitors with IC50 values below 0.3 nM. The compound with the best overall activities (36) was able to potentiate the anti-proliferative effect of doxorubicin in HeLa cells by at least 47-fold. Physicochemical, metabolic, and pharmacokinetic properties of selected inhibitors are also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.055